T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.44 SGD -2.22% Market Closed
Market Cap: 584.2m SGD
Have any thoughts about
Talkmed Group Ltd?
Write Note

Talkmed Group Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Talkmed Group Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
T
Talkmed Group Ltd
SGX:5G3
Note Receivable
S$198k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cordlife Group Ltd
SGX:P8A
Note Receivable
S$62.3m
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Q & M Dental Group (Singapore) Ltd
SGX:QC7
Note Receivable
S$2.4m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
23%
Healthway Medical Corporation Ltd
SGX:5NG
Note Receivable
S$36k
CAGR 3-Years
-75%
CAGR 5-Years
-55%
CAGR 10-Years
-52%
HC Surgical Specialists Ltd
SGX:1B1
Note Receivable
S$80k
CAGR 3-Years
N/A
CAGR 5-Years
-32%
CAGR 10-Years
N/A
EUDA Health Holdings Ltd
NASDAQ:EUDA
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Talkmed Group Ltd
Glance View

Market Cap
583.7m SGD
Industry
Health Care

TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).

5G3 Intrinsic Value
0.31 SGD
Overvaluation 30%
Intrinsic Value
Price
T

See Also

What is Talkmed Group Ltd's Note Receivable?
Note Receivable
198k SGD

Based on the financial report for Jun 30, 2024, Talkmed Group Ltd's Note Receivable amounts to 198k SGD.

What is Talkmed Group Ltd's Note Receivable growth rate?
Note Receivable CAGR 1Y
-47%

Over the last year, the Note Receivable growth was -47%.

Back to Top